Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Hemangiol Propranolol oral solution Infantile hemangioma Reimburse with clinical criteria and/or conditions Complete
Hemgenix etranacogene dezaparvovec Hemophilia B Reimburse with clinical criteria and/or conditions Complete
Hemlibra emicizumab Bleeding prevention, hemophilia A Reimburse with clinical criteria and/or conditions Complete
Hepsera Adefovir dipivoxil Hepatitis B Do not list Complete
Hepsera Adefovir dipivoxil Hepatitis B List with clinical criteria and/or conditions Complete
Holkira Pak Ombitasvir/paritaprevir/ritonavir and dasabuvir Hepatitis C, chronic List with clinical criteria and/or conditions Complete
Holkira Pak ombitasvir/paritaprevir/ritonavir and dasabuvir Hepatitis C, chronic Reimburse with clinical criteria and/or conditions Complete
Humira Adalimumab Arthritis, Rheumatoid List with clinical criteria and/or conditions Complete
Humira Adalimumab Arthritis, Psoriatic List with clinical criteria and/or conditions Complete
Humira Adalimumab ulcerative colitis Withdrawn